14
Phase 2–4 trials
Cardiomyopathy & ATTR amyloidosis · Live ClinicalTrials.gov data
Mavacamten (Camzyos) clinical trial pipeline
ClinicalTrials.gov lists 14 phase 2–4 trials for mavacamten, 1 of them actively recruiting. Refreshed daily — add up to four competitors to compare pipelines side by side.
6
Phase 3 trials
1
Actively recruiting
1,807
Participants across trials
Bristol-Myers Squibb
Lead sponsor by trial count
mavacamten (14)5 active2018–2029
mavacamten
'18
'19
'20
'21
'22
'23
'24
'25
'26
'27
'28
'29
mavacamten
MAVERICK-HCMP2
PIONEER-OLEP2
EXPLORER-HCMP3
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMP2
VALOR-HCMP3
EMBARK-HFpEFP2
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCMP3
HORIZON-HCMP3
ODYSSEY-HCMP3
MEMENTOP4
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic CardiomyopathyP3
A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)P4
BRAVE-HCMP4
CMI-SWITCHP4
Upcoming readouts
2 ahead · mavacamten
Select a trial to load its full ClinicalTrials.gov record.
Key mavacamten trials
Top 12 of the 14 registered phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07600177 | CMI-SWITCH — Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy | Phase 4 | Recruiting | Dec 2026 |
| NCT07103655 | BRAVE-HCM — The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruc… | Phase 4 | Not yet recruiting | Jul 2026 |
| NCT06112743 | MEMENTO — A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hyp… | Phase 4 | Active, not recruiting | Jul 2026 |
| NCT07004972 | A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER) | Phase 4 | Active, not recruiting | Dec 2027 |
| NCT06253221 | A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Active, not recruiting | Nov 2025 |
| NCT03470545 | EXPLORER-HCM — Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyop… | Phase 3 | Completed | Mar 2020 |
| NCT04349072 | VALOR-HCM — A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reductio… | Phase 3 | Completed | Feb 2022 |
| NCT05174416 | A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM | Phase 3 | Completed | Mar 2023 |
| NCT05414175 | HORIZON-HCM — A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Completed | Nov 2023 |
| NCT05582395 | ODYSSEY-HCM — A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Completed | Mar 2025 |
| NCT03442764 | MAVERICK-HCM — A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) | Phase 2 | Completed | Jan 2020 |
| NCT03496168 | PIONEER-OLE — Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Pre… | Phase 2 | Completed | Nov 2023 |
Related drug pipelines
FAQ
- How many clinical trials are running for mavacamten?
- ClinicalTrials.gov currently lists 14 phase 2–4 mavacamten trials: 4 phase 2, 6 phase 3, and 4 phase 4. 1 are actively recruiting.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare mavacamten against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.